Table 4.

Multivariable competing risks regression model using subdistribution hazard ratios to compare the cumulative incidence of biochemical recurrence across morphology indicators combining invasive cribriform cancer and intraductal carcinoma

Variable	SHR (95% CI)	P
Gleason 3	0.52 (0.31, 0.89)	0.016
Gleason 5	1.12 (0.64, 1.95)	0.70
Gleason 4 subpattern
Glomeruloid	0.74 (0.39, 1.41)	0.36
Cribriform or intraductal carcinoma	5.06 (2.21, 11.6)	< 0.001
Poorly formed	1.01 (0.49, 2.10)	0.97
Age (years)	0.99 (0.96, 1.03)	0.67
Pre-operative PSA (units)	1.003 (1.000, 1.006)	0.029
Lymph nodes removed	1.94 (0.88, 4.26)	0.10
Lymph nodes positive	1.78 (0.93, 3.42)	0.083
Positive margins	1.32 (0.78, 2.23)	0.30
Stage T2**	Ref.	Ref.
Stage T3a	2.78 (1.43, 5.43)	0.003
Stage T3b	4.47 (1.61, 12.5)	0.004

CI, confidence interval; PSA, prostate-specific antigen; SHR, subdistribution hazard ratio.

Statistically significant P values are highlighted in bold.

^**Omnibus test of association between stage and cumulative incidence of biochemical recurrence: P < 0.001.